Date of Conferral

10-26-2025

Degree

Doctor of Nursing Practice (DNP)

School

Nursing

Advisor

Corinne Romano

Abstract

The project is a Clinical Practice Guideline (CPG) for managing Gastrointestinal (GI) toxicities related to Glucagon-like Peptide-Receptor Agonist 1 (GLP-1RA) and Glucose-dependent insulinotropic polypeptide/Glucagon-like peptide-1Receptor Agonist (GIP/GLP-1RA) medications. Many patients are seeking weight loss with these agents, which cause GI toxicities that lead prescribers to have patients remain at lower doses that are sub-therapeutic or discontinue therapy. Advanced Practice Registered Nurses (APRNs) are prescribing these therapies for patients and lack an evidence-based CPG for properly managing the most common GI toxicities. APRNs can successfully monitor and manage GI symptoms to promote tolerability and treatment adherence. The project question focuses on searching the literature for support for the development of an evidence-based CPG for APRNs to assess and manage GI toxicities related to GLP-1RAs and GIP/GLP-1RA. The purpose of this CPG is to assist prescribers in assessing and managing drug-related gastrointestinal side effects to promote tolerability of therapeutic doses and achieve weight loss goals. The CPG was evaluated using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool to determine the quality and usability of the guideline. The expert panel review showed a favorable score in all six domains, gave the overall guideline assessment the highest score, and recommended the guideline for use in their clinics. The CPG will streamline decision-making with a standardized clinical approach, improving quality and consistency in managing GI toxicities. The advanced practice nursing profession may be positively impacted by elevating professional standards and highlighting the APRN’s role in improving patient outcomes.

Download

Included in

Nursing Commons

Share

 
COinS